Sugi Predict

Sugi Predict / Targets / ESRRG

ESRRG

Estrogen-related receptor gamma · P62508 · ESRRG on Sugi Atlas →

29,003 patent compounds predicted against ESRRG, 18,380 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Toremifene Toremifene (SCHEMBL7465) 0.91 13/20
Toremifene Toremifene (SCHEMBL4564) 0.70 11/20
Toremifene Toremifene (SCHEMBL177941) 0.70 11/20
SCHEMBL497984 SCHEMBL497984 0.56 11/20
SCHEMBL422472 SCHEMBL422472 0.53 10/20
Afimoxifene Afimoxifene (SCHEMBL9189) 1.00 8/20
Afimoxifene Afimoxifene (SCHEMBL640496) 1.00 8/20
Acetic Acid Acetic Acid (SCHEMBL547683) 0.46 8/20
Formaldehyde Formaldehyde (SCHEMBL332381) 0.59 7/20
SCHEMBL434849 SCHEMBL434849 0.55 7/20
SCHEMBL547594 SCHEMBL547594 0.48 7/20
SCHEMBL578488 SCHEMBL578488 0.40 7/20
SCHEMBL388066 SCHEMBL388066 0.59 6/20
SCHEMBL639036 SCHEMBL639036 0.51 6/20
SCHEMBL639037 SCHEMBL639037 0.51 6/20
SCHEMBL639038 SCHEMBL639038 0.51 6/20
Water Water (SCHEMBL547593) 0.50 6/20
SCHEMBL268871 SCHEMBL268871 0.49 6/20
SCHEMBL268872 SCHEMBL268872 0.49 6/20
SCHEMBL194099 SCHEMBL194099 0.43 6/20

Clinical trials — most relevant to ESRRG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men? PHASE4COMPLETED
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
Raloxifene and Rimostil for Perimenopause-Related Depression PHASE4COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women PHASE3COMPLETED
Maintenance Hormonal Therapy and DLBCL PHASE2/PHASE3NOT_YET_RECRUITING
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring PHASE3COMPLETED
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery PHASE3COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Phase II Study of Single Agent Lenvatinib PHASE2UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer PHASE2UNKNOWN
S-Equol in Alzheimer's Disease (SEAD) Trial PHASE1COMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Study of Biomarkers in Tissue Samples From Patients With Breast Cancer nanUNKNOWN
Epithelioid Haemangioendothelioma Observational Study nanRECRUITING
Sexual Hormones and Haemostasis: Observations for Women Health nanUNKNOWN
Imaging of ER Density to Guide and Improve Tailored Therapy for Acquired Anti-hormonal Resistant Breast Cancer nanCOMPLETED
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH nanWITHDRAWN
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus nanCOMPLETED
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741 nanCOMPLETED
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen nanUNKNOWN
Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer nanCOMPLETED
Tamoxifen Pharmacogenetics and Clinical Effects nanCOMPLETED
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients nanUNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Polymorphism of Estrogen Genes in Stroke nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ESRRG binder may also engage these)

ProteinNameSimilarity
Q5RAM2 — 1.000 Q5RAM2 →
P62510 — 1.000 P62510 →
P62509 — 1.000 P62509 →
ESRRB Steroid hormone receptor ERR2 0.999 landscape →
Q8HYL6 — 0.997 Q8HYL6 →
Q9XYB7 — 0.997 Q9XYB7 →
P28700 — 0.997 P28700 →
Q9XTJ4 — 0.996 Q9XTJ4 →
P51129 — 0.996 P51129 →
Q61539 — 0.996 Q61539 →
P79926 — 0.996 P79926 →
O35507 — 0.996 O35507 →
P57797 — 0.996 P57797 →
O45436 — 0.996 O45436 →
O18971 — 0.995 O18971 →
O17611 — 0.995 O17611 →
O01930 — 0.995 O01930 →
P51128 — 0.995 P51128 →
P37234 — 0.995 P37234 →
P49882 — 0.995 P49882 →
O62807 — 0.995 O62807 →
P23204 — 0.995 P23204 →
O18924 — 0.995 O18924 →
P45448 — 0.994 P45448 →
P37230 — 0.994 P37230 →
PPARA Peroxisome proliferator-activated receptor alpha 0.994 landscape →
Q7SYN5 — 0.994 Q7SYN5 →
Q90416 — 0.994 Q90416 →
P31396 — 0.994 P31396 →
P11475 — 0.994 P11475 →